Abstract
The issue of screening and treating populations for the presence of Helicobacter pylori infection in order to reduce the subsequent risk of gastric cancer has been a critical question since 1994 when the International Agency for Research on Cancer designated such infection as a definite cause of human cancer1. As it is unlikely that regulatory authorities would support the implementation of population-based screening and treatment in the absence of decisive results favouring such an intervention, a number of randomized trials have been initiated with the objective of providing the necessary evidence base. In particular, such trials are required in order to estimate the magnitude of benefit from the intervention and balance this against any associated adverse effects or risks2. To date there has been no precise quantification of either the benefits or risks in the context of population screening and it is generally accepted that rigorous randomized studies are essential to this process.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
IARC Working Group on the Evaluation of Carcinogenic Risk to Humans. Schistosomes, liver flukes and Helicobacter pylori. IARC Monogr Eval Carcinog Risks Hum. 1994; 61: 1–241.
Forman D. Should we go further and screen and treat? Eur J Gastroenterol Hepatol. 1999; 11 (Suppl. 2): S69–71.
Forman D. Lessons from ongoing intervention studies. In: Hunt RH, Tytgat GNJ, editors. Helicobacter pylori: Basic Mechanisms to Clinical Care 1998. Dordrecht: Kluwer; 1998: 354–61.
Sung JY, Lin S-R, Ching JVL et al. Atrophy and intestinal metaplasia one year after cure of H. pylori infection: a prospective, randomized study. Gastroenterology. 2000; 119: 7–14.
Correa P, Fontham ETH, Bravo JC et al. Chemoprevention of gastric dysplasia: randomized trial of antioxidant supplements and anti-Helicobacter pylori therapy. J Natl Cancer Inst. 2000; 92: 1881–8.
Sung JY, Lin SR, Leung WK, et al. Curing H. pylori infection reduces progression of premalignant gastric lesions: a prospective randomized study at 5-year follow-up. Gut. 2002; 51 (Suppl. 2): 1501.
Wong BCY, Lam S, Wong WM et al. Eradication of Helicobacter pylori infection significantly slows down the progression of precancerous lesions in high risk population: a 5-year prospective randomized study. Gastroenterology. 2002; 122 (Suppl. 1): W1215.
Wong BCY, Lam S, Wong WM et al. Eradicating Helicobacter pylori infection in general population prevents gastric cancer: a 7-year prospective randomized placebo-controlled study. Gastroenterology. 2002; 122 (Suppl. 1): W1216.
Buiatti E, Murioz N, Vivas J et al. Difficulty in eradicating Helicobacter pylori in a population at high risk for stomach cancer in Venezuela. Cancer Causes Control. 1994; 5: 249–54.
Miehlke S, Kirsch C, Dragosics B et al. Helicobacter pylori and gastric cancer: current status of the Austrian-Czech-German gastric cancer prevention trial (PRISMA-Study). World J Gastroenterol. 2001; 7: 243–7.
Blot WJ. Preventing cancer by disrupting progression of precancerous lesions. J Natl Cancer Inst. 2000; 92: 1868–9.
Dixon MF. Atrophy, metaplasia and dysplasia — a risk for cancer: are they reversible? In: Hunt RH, Tytgat GNJ, editors. Helicobacter pylori: Basic Mechanisms to Clinical Care 1998. Dordrecht: Kluwer; 1998: 336–53.
Genta RM. A year in the life of the gastric mucosa. Gastroenterology. 2000; 119: 252–4.
Ley C, Parsonnet J. Helicobacter pylori infection and gastric cancer. Gastroenterology. 2001; 120: 324.
Uemura N, Mukai T, Okamoto S et al. Effect of Helicobacter pylori eradication on subsequent development of cancer after endoscopic resection of early gastric cancer. Cancer Epidemid Biol Prey. 1997; 6: 639–42.
Uemura N, Okamoto S. Effect of Helicobacter pylori eradication on subsequent development of cancer after endoscopic resection of early gastric cancer in Japan. Gastroenterol Clin N Am. 2000; 29: 819–23.
Uemura N, Okamato S, Yamamoto S et al. Helicobacter pylori infection and the development of gastric cancer. New Engl J Med. 2001; 345: 784–9.
Ohkusa T, Fujiki K, Takashimizu I et al. Improvement in atrophic gastritis and intestinal metaplasia in patients in whom Helicobacter pylori was eradicated. Ann Intern Med. 2001; 134: 380–6.
Signorello LB, Ye WM, Fryzek JP et al. Nationwide study of cancer risk among hip replacement patients in Sweden. J Natl Cancer Inst. 2001; 93: 1405–10.
Olsen JH, McLaughlin JK, Nyren O et al. Hip and knee implantations among patients with osteoarthritis and risk of cancer: a record-linkage study from Denmark. Int J Cancer. 1999; 81: 719–22.
Akre K, Signorello LB, Engstrand L et al. Risk for gastric cancer after antibiotic prophylaxis in patients undergoing hip replacement. Cancer Res. 2000; 60: 6376–80.
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2003 Springer Science+Business Media Dordrecht
About this chapter
Cite this chapter
Forman, D. (2003). Results of intervention trials in Helicobacter pylori-infected populations. In: Hunt, R.H., Tytgat, G.N.J. (eds) Helicobactor pylori. Springer, Dordrecht. https://doi.org/10.1007/978-94-017-1763-2_23
Download citation
DOI: https://doi.org/10.1007/978-94-017-1763-2_23
Publisher Name: Springer, Dordrecht
Print ISBN: 978-90-481-5778-5
Online ISBN: 978-94-017-1763-2
eBook Packages: Springer Book Archive